Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.

Journal: Frontiers in immunology
PMID:

Abstract

BACKGROUND: Cancer remains a leading cause of mortality worldwide. A non-invasive screening solution was required for early diagnosis of cancer. Multi-cancer early detection (MCED) tests have been considered to address the challenge by simultaneously identifying multiple types of cancer within a single test using minimally invasive blood samples. However, a multi-cancer screening strategy utilizing urine-based metabolomics has not yet been developed.

Authors

  • Xinping Xu
    Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Chunyan Zeng
    The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Bei Qing
    The Second Xiangya Hospital of Central South University, Changsha, China.
  • Yun He
    Metanotitia Inc., Shenzhen, China.
  • Guodong Song
    The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Jiaojiao Wang
    Metanotitia Inc., Shenzhen, China.
  • Shuqi Yu
    Metanotitia Inc., Shenzhen, China.
  • Tao Zhang
    Department of Traumatology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, 40044, People's Republic of China.
  • Qingyan Wei
    Metanotitia Inc., Shenzhen, China.
  • Li Liu
    Metanotitia Inc., Shenzhen, China.
  • He Wen
    Metanotitia Inc., Shenzhen, China.
  • Junyuan Hu
    Metanotitia Inc., Shenzhen, China.
  • Wei Zhang
    The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yan Li
    Interdisciplinary Research Center for Biology and Chemistry, Liaoning Normal University, Dalian, China.
  • Youxiang Chen
    The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Zhenkun Xia
    The Second Xiangya Hospital of Central South University, Changsha, China.